Population PK–PD model for Fc-osteoprotegerin in healthy postmenopausal women
暂无分享,去创建一个
Paolo Vicini | Mark C. Peterson | Marc R. Gastonguay | Steven W. Martin | P. Vicini | P. Bekker | M. Gastonguay | M. Zierhut | Matthew L. Zierhut | P. Leese | Donna Holloway | M. Peterson | D. Holloway | Pirow J. Bekker | Philip T. Leese
[1] M. Ettinger,et al. Aging bone and osteoporosis: strategies for preventing fractures in the elderly. , 2003, Archives of internal medicine.
[2] M. Rubin,et al. The anabolic effects of parathyroid hormone therapy. , 2003, Clinics in geriatric medicine.
[3] E N Jonsson,et al. Xpose--an S-PLUS based population pharmacokinetic/pharmacodynamic model building aid for NONMEM. , 1999, Computer methods and programs in biomedicine.
[4] Hartmut Derendorf,et al. Pharmacokinetic/pharmacodynamic studies in drug product development. , 2002, Journal of pharmaceutical sciences.
[5] S. Cremers,et al. A pharmacokinetic and pharmacodynamic model for intravenous bisphosphonate (pamidronate) in osteoporosis , 2002, European Journal of Clinical Pharmacology.
[6] K. Blesch,et al. Clinical Pharmacokinetic/Pharmacodynamic and Physiologically based Pharmacokinetic Modeling in New Drug Development: The Capecitabine Experience , 2003, Investigational New Drugs.
[7] A. Nakanishi,et al. The Effect of a Single Dose of Osteoprotegerin in Postmenopausal Women , 2001, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.
[8] Roberto Gomeni,et al. In Silico Prediction of Optimal in Vivo Delivery Properties Using Convolution-Based Model and Clinical Trial Simulation , 2004, Pharmaceutical Research.
[9] Stephen Duffull,et al. Modeling and Simulation for Clinical Trial Design Involving a Categorical Response: A Phase II Case Study with Naratriptan , 2001, Pharmaceutical Research.
[10] R. Eastell,et al. Relationship of Early Changes in Bone Resorption to the Reduction in Fracture Risk With Risedronate , 2003, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.
[11] L. Sheiner,et al. Evaluating Pharmacokinetic/Pharmacodynamic Models Using the Posterior Predictive Check , 2001, Journal of Pharmacokinetics and Pharmacodynamics.
[12] D. Ruppert,et al. Transformation and Weighting in Regression , 1988 .
[13] J F Boisvieux,et al. Alternative approaches to estimation of population pharmacokinetic parameters: comparison with the nonlinear mixed-effect model. , 1984, Drug metabolism reviews.
[14] J. Gobburu,et al. Application of modeling and simulation to integrate clinical pharmacology knowledge across a new drug application. , 2002, International journal of clinical pharmacology and therapeutics.
[15] L. Hofbauer,et al. The OPG/RANKL/RANK system in metabolic bone diseases. , 2004, Journal of musculoskeletal & neuronal interactions.
[16] Timothy Goggin,et al. A semimechanistic and mechanistic population PK-PD model for biomarker response to ibandronate, a new bisphosphonate for the treatment of osteoporosis. , 2004, British journal of clinical pharmacology.
[17] M. Draper. The Role of Selective Estrogen Receptor Modulators (SERMs) in Postmenopausal Health , 2003, Annals of the New York Academy of Sciences.
[18] David L. Lacey,et al. Osteoclast differentiation and activation , 2003, Nature.
[19] K. Åkesson. New approaches to pharmacological treatment of osteoporosis. , 2003, Bulletin of the World Health Organization.
[20] W. Colburn,et al. Biomarkers in Drug Discovery and Development: From Target Identification through Drug Marketing , 2003, Journal of clinical pharmacology.
[21] A. van Peer,et al. A Model with Separate Hepato-Portal Compartment ("First-Pass" Model): Fitting to Plasma Concentration-Time Profiles in Humans , 1997, Pharmaceutical Research.
[22] Ivan A. Nestorov,et al. Sensitivity Analysis of Pharmacokinetic and Pharmacodynamic Systems: I. A Structural Approach to Sensitivity Analysis of Physiologically Based Pharmacokinetic Models , 1999, Journal of Pharmacokinetics and Biopharmaceutics.
[23] N H Holford,et al. Simulation of clinical trials. , 2000, Annual review of pharmacology and toxicology.